Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.61 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012584 | 1.00 | CES2 (0.61) | CES2CES1ALDH1A1GAAMAPT | |
| SCHEMBL30301996 | 0.86 | SLC6A4 (0.51) | CES2CES1ALDH1A1GAAMAPT | |
| SCHEMBL2708451 | 0.86 | SLC6A4 (0.51) | CES2CES1ALDH1A1GAAMAPT | |
| SCHEMBL2941745 | 0.85 | SLC6A3 (0.57) | CES2CES1ALDH1A1MAPTKDM4E | |
| SCHEMBL30954392 | 0.85 | CES2 (0.68) | CES2CES1ALDH1A1GAAMAPT | |
| SCHEMBL112046 | 0.84 | CES2 (0.61) | CES2CES1ALDH1A1MAPTKDM4E | |
| SCHEMBL8359445 | 0.83 | CES2 (0.65) | CES2CES1ALDH1A1GAAMAPT | |
| SCHEMBL5651048 | 0.83 | CES2 (0.65) | CES2CES1ALDH1A1GAAMAPT | |
| SCHEMBL21274571 | 0.83 | HPGD (0.52) | CES2CES1ALDH1A1GAAKDM4E | |
| SCHEMBL23607068 | 0.82 | SLC6A4 (0.49) | CES2CES1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | claimed |
| CN-120044163-A | HPLC analysis and detection method for 2,4, 6-trifluoro benzoyl chloride and related substances thereof | 复星万邦(江苏)医药集团有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | claimed |
| CN-116505058-B | Negative electrode interface modification method of solid-state lithium battery | 河南师范大学 | 2024-02-13 | — | — | CN | claimed |
| CN-116505058-A | Negative electrode interface modification method of solid-state lithium battery | 河南师范大学 | 2023-07-28 | — | — | CN | claimed |
| CN-115306376-A | Oil-gas well fracturing monitoring reagent, method and application thereof | 中国石油天然气股份有限公司 | 2022-11-08 | — | — | CN | claimed |
| US-20220315555-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2022-10-06 | — | — | US | claimed |
| CN-114865080-A | Lithium ion battery electrolyte and lithium ion battery | 香河昆仑新能源材料股份有限公司 | 2022-08-05 | — | — | CN | claimed |
| US-20210221789-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2021-07-22 | — | — | US | claimed |
| US-20200231566-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2020-07-23 | — | — | US | claimed |
| EP-3656771-A1 | PROCESS FOR THE PREPARATION OF A SYNTHETIC INTERMEDIATE FOR APOPTOSIS-INDUCING AGENTS | AbbVie Ireland Unlimited Company (IE) | 2020-05-27 | — | — | EP | claimed |
| US-20190119247-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2019-04-25 | — | — | US | claimed |
| CN-107089981-A | A kind of inhibitor Venetoclax of BCL 2 synthetic method | 杭州科耀医药科技有限公司 | 2017-08-25 | — | — | CN | claimed |
| CN-106565734-A | Psoralen ester derivatives and applications thereof | 中国科学院新疆理化技术研究所 | 2017-04-19 | — | — | CN | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-5116844-A | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER INC. (US) | 1992-05-26 | — | — | US | disclosed |
| CN-1040795-A | The preparation method of triazole species antimycotic agent | PFIZER (US) | 1990-03-28 | — | — | CN | disclosed |
| EP-0357241-A1 | Triazole antifungal agents | Pfizer Limited (GB) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | CES2 2605/4885CES1 1398/4885ALDH1A1 2556/4885 |
| US-20210221789-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CES2 4241/4885CES1 4153/4885ALDH1A1 4238/4885 |
| US-20220315555-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CES2 4241/4885CES1 4153/4885ALDH1A1 4238/4885 |
| US-20190119247-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CES2 4241/4885CES1 4153/4885ALDH1A1 4238/4885 |
| US-20200231566-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CES2 4241/4885CES1 4153/4885ALDH1A1 4238/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | CES2 3298/4885CES1 2403/4885ALDH1A1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.